HAPLN4: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: HAPLN4

NCBI ID: G404037

HAPLN4

HAPLN4: A Potential Drug Target Or Biomarker for Various Diseases

HAPLN4, also known as HPLN4_HUMAN, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

HAPLN4 is a non-coding RNA molecule that is expressed in various tissues and cells of the human body. It is a key regulator of the hematopoietic stem cell (HSC) proliferation and differentiation, and has been shown to play a role in the development and progression of various diseases.

One of the key functions of HAPLN4 is its role in the regulation of stem cell proliferation. HAPLN4 has been shown to promote the proliferation of HSCs, which are immature cells that have the ability to develop into any cell in the body. This process is critical for the development and maintenance of tissues and organs, including blood cells, neurons, and tissues.

In addition to its role in stem cell proliferation, HAPLN4 has also been shown to play a key role in the regulation of cell death. HAPLN4 has been shown to promote the programmed cell death, also known as apoptosis, which is a natural process that helps remove damaged or dysfunctional cells from the body. This process is important for maintaining the health and function of tissues and organs, and is a potential target for the treatment of diseases where cell death is abnormal or occurs too frequently.

HAPLN4 has also been shown to play a role in the regulation of inflammation. HAPLN4 has been shown to regulate the production of pro-inflammatory cytokines, which are molecules that contribute to inflammation. This regulation is important for maintaining a balance between inflammation and inflammation-resistance, and is a potential target for the treatment of autoimmune disorders.

In addition to its potential therapeutic applications, HAPLN4 has also been shown to be a potential biomarker for a variety of diseases. For example, HAPLN4 has been shown to be expressed in various types of cancer, and has been shown to be involved in the development and progression of these diseases. In addition, HAPLN4 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

Overall, HAPLN4 is a gene that has significant potential as a drug target or biomarker for the treatment of various diseases. Further research is needed to fully understand its functions and to develop effective treatments based on these functions.

Protein Name: Hyaluronan And Proteoglycan Link Protein 4

Functions: Essential for the proper localization of brevican (BCAN), mainly as a perineuronal nets (PNNs)-type deposition in the brainstem and cerebellum thereby playing a key role in the formation and structural organization of PNNs (By similarity). Contributes to the formation and transmission of inhibitory GABAergic synapses between Purkinje cells and deep cerebellar nuclei neurons (By similarity)

The "HAPLN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HAPLN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets